SCHEMBL957930

SCHEMBL957930

O=C(CCC(=O)Oc1ccc([N+](=O)[O-])cc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 1/20 0.81
CTNNB1 P35222 1/20 0.81
GAA P10253 1/20 0.59
PTPN7 P35236 1/20 0.57
PTPN12 Q05209 1/20 0.57
PTPN22 Q9Y2R2 1/20 0.57
KMT2A Q03164 5/20 0.55
MAPT P10636 4/20 0.55
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
LMNA P02545 1/20 0.55
HTT P42858 1/20 0.55
HSD17B10 Q99714 1/20 0.55
PKM P14618 1/20 0.54
MGLL Q99685 2/20 0.53
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CES2 O00748 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091851 0.93 BCL9 (0.71) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL3919600 0.93 BCL9 (0.76) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL531007 0.93 BCL9 (0.76) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL27557226 0.92 BCL9 (0.74) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL13701877 0.92 BCL9 (0.69) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL570540 0.91 BCL9 (0.73) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL2607873 0.91 BCL9 (0.73) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL530771 0.91 BCL9 (0.73) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL7079988 0.91 BCL9 (0.73) BCL9CTNNB1GAAPTPN7PTPN12
SCHEMBL531155 0.91 BCL9 (0.73) BCL9CTNNB1GAAPTPN7PTPN12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3474890-B1 PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION MAX PLANCK GESELLSCHAFT (DE) 2026-05-06 EP disclosed
EP-4729073-A1 SYNTHETIC VACCINES AGAINST FRANCISELLA TULARENSIS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-04-22 EP disclosed
EP-4682154-A1 PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF OLIGOSACCHARIDES REPRESENTING SEGMENTS OF O-ANTIGENS FROM DIVERSE SHIGELLA FLEXNERI SEROTYPES Institut Pasteur (FR) 2026-01-21 EP disclosed
WO-2025215228-A1 SYNTHETIC VACCINES AGAINST PORPHYROMONAS GINGIVALIS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-10-16 WO disclosed
EP-4631951-A1 SYNTHETIC VACCINES AGAINST PORPHYROMONAS GINGIVALIS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-10-15 EP disclosed
US-12043643-B2 Vaccine against klebsiella pneumoniae IDORSIA PHARMACEUTICALS LTD (CH) 2024-07-23 US disclosed
CN-111448205-B Vaccine against klebsiella pneumoniae 爱杜西亚药品有限公司 2024-05-14 CN disclosed
WO-2024028192-A1 USE OF CONJUGATES OF HUMAN SERUM ALBUMIN AND PHOSPHOCHOLINE FOR BLOCKING C-REACTIVE PROTEIN PENTRACOR GMBH (DE) 2024-02-08 WO disclosed
US-20240024489-A1 PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF INSTITUT PASTEUR (FR) 2024-01-25 US disclosed
US-11850309-B2 Cationic materials and formulations for drug delivery THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2023-12-26 US disclosed
WO-1992022583-A2 TRI- AND TETRA-VALENT MONOSPECIFIC ANTIGEN-BINDING PROTEINS CELLTECH LIMITED (GB) 1992-12-23 WO disclosed
EP-0457438-A2 Conjugate compounds containing aza-macrocycles, and processes for their preparation CELLTECH THERAPEUTICS LIMITED (GB) 1991-11-21 EP disclosed
WO-1991016078-A1 CONJUGATE COMPOUNDS CONTAINING AZA-MACROCYCLES, AND PROCESSES FOR THEIR PREPARATION CELLTECH LIMITED (GB) 1991-10-31 WO disclosed
WO-1991000285-A1 TRI-AZA MACROCYCLES AND PROCESSES FOR THEIR PREPARATION CELLTECH LIMITED (GB) 1991-01-10 WO disclosed
EP-0404605-A2 Tri-aza macrocycles and processes for their production CELLTECH THERAPEUTICS LIMITED (GB) 1990-12-27 EP disclosed
US-4883864-A COUPLED AND FREE AMINE GROUPS CAPPED WITH UREA OR AMIDE GROUPS, EYE SURGERY MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-11-28 US disclosed
US-4851513-A Viscoelastic collagen solution for opthalmic use and method of preparation MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-07-25 US disclosed
US-4713446-A COLLAGEN COUPLED TO CARBONYL OR SULFONYL GROUPS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-12-15 US disclosed
EP-0214853-A2 Viscoelastic collagen solution for ophthalmic use and method of preparation MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-03-18 EP disclosed
US-4181661-A SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS MERCK & CO., INC. (US) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024489-A1 PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF SI, DAD1, FUT5 BCL9 3994/4885CTNNB1 3389/4885GAA 613/4885
US-11850309-B2 Cationic materials and formulations for drug delivery SLC7A1, SLC43A1, AADAT BCL9 3485/4885CTNNB1 2544/4885GAA 1750/4885
US-12043643-B2 Vaccine against klebsiella pneumoniae SLC11A2, OSTC, STT3A BCL9 3206/4885CTNNB1 4394/4885GAA 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.